A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer.

Investigational New Drugs
Elaina M GartnerMark M Zalupski

Abstract

Tetrathiomolybdate (TM) is an oral copper chelator under development as an anti-angiogenic agent. We evaluated TM in combination with irinotecan, 5-fluorouracil, and leucovorin (IFL). Serum vascular endothelial growth factor (VEGF), basic fibroblast growth factor, interleukin 6 (IL-6), and IL-8 were measured to evaluate the anti-angiogenic effect. Twenty-four patients with metastatic colorectal cancer were treated. The combination with IFL was well tolerated and dose intensity of IFL was maintained during combination therapy with TM. By intention to treat analysis, the overall response rate (RR) was 25% (95% CI 9.8-46.7) and the median time to progression (TTP) was 5.6 months (95% CI 2.7-7.7). VEGF levels were correlated with TTP, as were changes in VEGF, IL-8, and IL-6. TM can be safely added to IFL without compromising dose intensity or diminishing the expected RR. Changes in serum VEGF, IL-8, and IL-6 after treatment may directly reflect changes in CRC tissue angiogenesis.

References

Sep 1, 1994·Diseases of the Colon and Rectum·T J SaclaridesD B Rubin
Sep 28, 2000·The New England Journal of Medicine·L B SaltzL L Miller
Feb 22, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R T PoonJ Wong
Mar 10, 2001·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·R BrollU Windhövel
May 28, 2004·Endocrine-related Cancer·V L GoodmanS D Merajver
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Feb 4, 2005·The New England Journal of Medicine·Jeffrey A Meyerhardt, Robert J Mayer

❮ Previous
Next ❯

Citations

May 21, 2005·Diseases of the Colon and Rectum·Robert R McWilliams, Charles Erlichman
Apr 1, 2010·Journal of Developmental Origins of Health and Disease·C M Anderson, W T Johnson
Feb 15, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S JainL T Vahdat
Nov 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Quintin PanSofia D Merajver
Apr 12, 2012·Molecular Cancer Therapeutics·Siqing FuRazelle Kurzrock
Dec 14, 2011·American Journal of Respiratory Cell and Molecular Biology·Harm J BogaardNorbert F Voelkel
Sep 10, 2014·Journal of Trace Elements in Medicine and Biology : Organ of the Society for Minerals and Trace Elements (GMS)·George J Brewer
Apr 2, 2009·Expert Opinion on Investigational Drugs·Gazala Khan, Sofia Merajver
Apr 30, 2010·Journal of Inorganic Biochemistry·Yasumitsu OgraYasumi Anan
Feb 23, 2010·Translational Research : the Journal of Laboratory and Clinical Medicine·Fred AskariGeorge J Brewer
Nov 26, 2009·Translational Research : the Journal of Laboratory and Clinical Medicine·George J Brewer
Jun 24, 2016·Metallomics : Integrated Biometal Science·Kyung Chan ParkDes R Richardson
Dec 5, 2018·Journal of the American College of Nutrition·Taylor C WallaceLinda T Vahdat
Feb 12, 2020·International Journal of Molecular Sciences·Silvia BaldariGabriele Toietta
Oct 28, 2019·International Journal of Molecular Sciences·Ssu-Yu ChenShih-Ming Huang
May 15, 2019·Cancers·Silvia BaldariGabriele Toietta

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.